Utah Medical Products Inc. Common Stock (UTMD)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for simple businesses with durable demand, high margins, and a balance sheet that lets them sleep at night. Utah Medical Products fits parts of that: 140 employees, niche devices for labor and delivery, and a 31.49% net margin in fiscal Q2 2026, the quarter ended 2026-06-30, with revenue of $8.5M and net income of $2.7M. But the longer record is not growth; it is erosion. Fiscal 2025 revenue was $38.5M and net income was $11.3M, down from $40.9M and $13.9M in fiscal 2024, and from $50.2M and $16.6M in fiscal 2023. Diluted EPS fell from $4.57 in fiscal 2023 to $3.96 in fiscal 2024 and $3.48 in fiscal 2025. The Lynch category computed by FairStock is slow grower, with profit 0.9% a year over five years and revenue -1.8%. The balance sheet is a fortress: D/E 0.00 and an Altman Z-Score of 58.78. Free cash flow is $11.4M, a 4.8% FCF yield, and the dividend yield is 1.67%. Returns are modest, however: ROE 8.76% and ROCE 6.10%. At $74.71 on 2026-10-13, FairStock calculations show P/E 22.78, P/B 1.98, EV/EBITDA 11.43, and a Graham Number of $53.19, leaving the price about 40% above that conservative yardstick. Piotroski is 6/9. I would want evidence of stabilization or a wider margin of safety before calling this cheap.

In plain English: Utah Medical Products makes niche medical devices used in childbirth, breathing support, blood pressure monitoring, and dialysis. The business has high profit margins and no debt, but sales and profits have shrunk from earlier years. At the recent price, the shares look more than fair, and possibly expensive relative to current earnings and asset value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer